Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17055081 | ABHD12 INHIBITORS AND METHODS OF MAKING AND USING SAME | November 2020 | September 2023 | Allow | 34 | 1 | 0 | No | No |
| 17053273 | KRAS G12C INHIBITORS | November 2020 | November 2023 | Allow | 36 | 0 | 0 | Yes | No |
| 17050792 | Pyridazine Derivatives as SMARCA2/4 Degraders | October 2020 | December 2023 | Allow | 37 | 1 | 0 | Yes | No |
| 16962809 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | July 2020 | October 2023 | Allow | 39 | 2 | 0 | No | No |
| 16488912 | METHOD AND COMPOSITION FOR TREATING EATING DISORDERS | August 2019 | July 2024 | Abandon | 59 | 2 | 1 | No | Yes |
| 15788181 | METHOD OF SYNTHESIZING OF 3-OXOLUPENAL NANOPARTICLES | October 2017 | September 2018 | Allow | 11 | 1 | 1 | Yes | No |
| 15555693 | PLATINUM PRODRUGS AND METHODS OF MAKING AND USING THEREOF | September 2017 | June 2019 | Allow | 21 | 2 | 1 | Yes | No |
| 15124096 | TRICYCLIC PRODRUGS | September 2016 | May 2018 | Allow | 20 | 1 | 1 | Yes | No |
| 15255910 | QUINOXALINYL-PIPERAZINAMIDE METHODS OF USE | September 2016 | December 2017 | Allow | 16 | 2 | 0 | Yes | No |
| 15113634 | SMC COMBINATION THERAPY FOR THE TREATMENT OF CANCER | July 2016 | May 2019 | Allow | 34 | 1 | 1 | No | No |
| 15213829 | Methods for Treating Cancer Using Apilimod | July 2016 | March 2019 | Allow | 32 | 3 | 1 | No | No |
| 15036132 | SULFUR-SUBSTITUTED PODOPHYLLOTOXIN DERIVATIVE, SYNTHESIS METHOD THEREOF, AND USE THEREOF | May 2016 | July 2017 | Allow | 14 | 1 | 0 | No | No |
| 15091816 | TREATMENT OF LUNG CANCER WITH INHIBITORS OF GLUTAMINASE | April 2016 | June 2019 | Allow | 38 | 3 | 1 | Yes | Yes |
| 15022654 | TREATING NEURODEGENERATIVE DISEASE WITH FENOFIBRATE AND ANALOGS THEREOF | March 2016 | February 2025 | Abandon | 60 | 9 | 1 | Yes | Yes |
| 15044231 | PYRAZOLO[3,4-C]PYRIDINE COMPOUNDS AND METHODS OF USE | February 2016 | August 2017 | Allow | 18 | 2 | 1 | Yes | No |
| 14896426 | SUBSTITUTED TRIAZOLOPYRIDINES | December 2015 | January 2017 | Allow | 14 | 1 | 0 | No | No |
| 14774623 | MODULATION OF CELLULAR DNA REPAIR ACTIVITY TO INTERCEPT MALIGNANCY | September 2015 | September 2018 | Allow | 36 | 2 | 1 | Yes | No |
| 14802036 | COMBINATIONS COMPRISING 3-PHENYLSULFONYL-8-PIPERAZINYL-1YL-QUINOLINE | July 2015 | June 2017 | Allow | 23 | 2 | 1 | Yes | No |
| 14649721 | POLYALKOXYLATED ALCOHOLS AS EXCIPIENTS FOR PHARMACEUTICAL COMPOSITIONS | June 2015 | December 2016 | Allow | 19 | 2 | 1 | Yes | No |
| 14727146 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER | June 2015 | August 2016 | Allow | 15 | 1 | 0 | No | No |
| 14711355 | TREATMENT OF DISORDERS ASSOCIATED WITH G PROTEIN-COUPLED RECEPTOR 35 (GPR35) | May 2015 | December 2016 | Allow | 19 | 1 | 1 | No | No |
| 14337397 | Rhinitis Treatment Regimens | July 2014 | June 2016 | Allow | 23 | 1 | 0 | No | No |
| 14070718 | TREATMENT FOR RECYCLING FRACTURE WATER - GAS AND OIL RECOVERY IN SHALE DEPOSITS | November 2013 | October 2015 | Allow | 23 | 1 | 0 | No | No |
| 14068657 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, AND THEIR PREPARATION AND USE | October 2013 | November 2016 | Allow | 37 | 1 | 1 | Yes | No |
| 14025986 | Macrocyclic Compounds as ALK, FAK and JAK2 Inhibitors | September 2013 | July 2016 | Allow | 34 | 1 | 1 | Yes | No |
| 13932385 | 5-HT1A RECEPTOR SUBTYPE AGONIST | July 2013 | December 2014 | Allow | 17 | 2 | 1 | Yes | No |
| 13823792 | 17A-HYDROXYLASE/C17,20-LYASE INHIBITORS | June 2013 | September 2014 | Allow | 18 | 1 | 1 | Yes | No |
| 13877204 | SUBSTITUTED N-(2-ARYLAMINO)ARYL SULFONAMIDE-CONTAINING COMBINATIONS | June 2013 | March 2016 | Allow | 35 | 1 | 1 | Yes | No |
| 13635734 | IMIDAZOPYRAZINES | April 2013 | March 2016 | Allow | 42 | 1 | 1 | No | No |
| 13823604 | FUSED HETEROARYLS AND THEIR USES | March 2013 | August 2015 | Allow | 29 | 2 | 1 | Yes | No |
| 13665133 | INHIBITOR OF THE DIFFERENTIATION OF T CELLS INTO TH1 CELLS | October 2012 | November 2014 | Allow | 24 | 2 | 0 | No | No |
| 13654884 | POTENTIATION OF CANCER CHEMOTHERAPY BY 7-(2, 5- DIHYDRO- 4-IMIDAZO [1, 2-A] PYRIDINE-3-YL-2,5-DIOXO-IH-PYRROL-3-YL)-9-FLUORO-1,2,3,4 TETRAHYDRO -2-(1-PIPERIDINYL-CARBONYL)-PYRROLO [3,2,1-JK] [1,4] BENZODIAZEPINE | October 2012 | October 2013 | Allow | 12 | 1 | 1 | No | No |
| 13637161 | BENZONAPHTHYRIDINAMINES AS AUTOTAXIN INHIBITORS | September 2012 | January 2015 | Allow | 27 | 1 | 0 | Yes | No |
| 13509047 | FLUORO-SUBSTITUTED 2-ARYL-3,5-DICYANO-4-INDAZOLYL-6-METHYL-1,4-DIHYDROPYRIDINES AND USES THEREOF | September 2012 | December 2014 | Allow | 31 | 1 | 0 | No | No |
| 13530025 | FORMULATIONS AND METHODS FOR VASCULAR PERMEABILITY-RELATED DISEASES OR CONDITIONS | June 2012 | March 2013 | Allow | 9 | 0 | 1 | No | No |
| 13260990 | Inhibiting EPH B-3 Kinase | May 2012 | August 2014 | Allow | 35 | 1 | 1 | Yes | No |
| 13359213 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | January 2012 | April 2015 | Allow | 39 | 2 | 1 | Yes | No |
| 13001914 | IMMUNOSUPPRESSOR BASED ON THE BLOCKAGE OF TCR-NCK INTERACTION | January 2012 | October 2013 | Allow | 34 | 0 | 0 | Yes | No |
| 13386288 | TREATMENT OF DISORDERS ASSOCIATED WITH G PROTEIN-COUPLED RECEPTOR 35 (GPR35) | January 2012 | January 2015 | Allow | 36 | 2 | 1 | Yes | No |
| 13254235 | INHIBITORS OF ANAPHASE PROMOTING COMPLEX ACTIVITY | December 2011 | September 2015 | Allow | 49 | 2 | 1 | Yes | No |
| 13318904 | Heterocyclic Substituted Acardite Derivate and Application Thereof | November 2011 | October 2014 | Allow | 35 | 1 | 1 | No | No |
| 13259464 | HETEROCYCLIC COMPOUNDS AS AUTOTAXIN INHIBITORS | September 2011 | May 2014 | Allow | 32 | 2 | 1 | No | No |
| 13209937 | MATERIALS AND METHODS FOR TREATMENT OF CANCER AND IDENTIFICATION OF ANTI-CANCER COMPOUNDS | August 2011 | November 2013 | Allow | 27 | 1 | 1 | Yes | No |
| 13123166 | PROTEIN PHOSPHATASE INHIBITOR | June 2011 | January 2014 | Allow | 34 | 0 | 1 | No | No |
| 13126484 | P70 S6 KINASE INHIBITOR AND EGFR INHIBITOR COMBINATION THERAPY | April 2011 | October 2012 | Allow | 18 | 2 | 0 | No | No |
| 13094015 | BICYCLIC COMPOUND | April 2011 | January 2014 | Allow | 33 | 1 | 1 | No | No |
| 13124180 | INHIBITORS OF AKT ACTIVITY | April 2011 | July 2013 | Allow | 27 | 0 | 1 | No | No |
| 13080071 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE | April 2011 | August 2014 | Allow | 41 | 4 | 1 | No | No |
| 13027428 | CHROMENONE DERIVATIVES | February 2011 | June 2012 | Allow | 16 | 2 | 2 | No | No |
| 13015734 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, AND THEIR PREPARATION AND USE | January 2011 | August 2013 | Allow | 31 | 0 | 1 | No | No |
| 12988975 | N-Acylthiourea and N-Acylurea Inhibitors of the Hedgehog Protein Signalling Pathway | January 2011 | February 2015 | Allow | 52 | 2 | 1 | Yes | No |
| 12809674 | SUBSTITUTED AZABICYCLIC COMPOUNDS AND THE USE THEREOF | September 2010 | August 2013 | Allow | 38 | 1 | 1 | Yes | No |
| 12877202 | 4-SUBSTITUTED PYRIDIN-3-YL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | September 2010 | February 2013 | Allow | 29 | 2 | 1 | Yes | No |
| 12682874 | Human Adam-10 Inhibitors | August 2010 | December 2012 | Allow | 32 | 2 | 1 | Yes | No |
| 12856196 | PYRIDINIUM AND QUINOLINIUM DERIVATIVES | August 2010 | March 2013 | Allow | 31 | 1 | 1 | Yes | No |
| 12841976 | Tubulysin compounds with high cytotoxicity, pharmaceutical compositions thereof, and method of use thereof | July 2010 | June 2013 | Allow | 35 | 2 | 1 | Yes | No |
| 12741862 | SMAC MIMETIC COMPOUNDS AS APOPTOSIS INDUCERS | June 2010 | August 2013 | Allow | 39 | 1 | 1 | Yes | No |
| 12816223 | ANTHRACENEDIONE COMPOUNDS | June 2010 | March 2013 | Allow | 33 | 1 | 1 | Yes | No |
| 12746968 | COMBINATIONS COMPRISING 3-PHENYLSULFONYL-8-PIPERAZINYL-1YL-QUINOLINE | June 2010 | March 2015 | Allow | 57 | 3 | 0 | No | No |
| 12787937 | Pharmaceutical Compositions for the Treatment of Pain | May 2010 | December 2014 | Allow | 55 | 3 | 1 | Yes | No |
| 12734026 | NOVEL HISTONE DEACETYLASE INHIBITORS | May 2010 | March 2013 | Allow | 35 | 1 | 1 | Yes | No |
| 12772861 | METHOD FOR THE TREATMENT OF ACNE USING COMPOSITIONS COMPRISING 0.3% BY WEIGHT OF 6-[3-(1-ADAMANTYL)-4-METHOXYPHENYL]-2-NAPHTHOIC ACID | May 2010 | October 2010 | Allow | 6 | 0 | 0 | Yes | No |
| 12680640 | METHOD OF TREATING SENSORIMOTOR DISORDERS WITH ALPHA-2 ADRENERGIC RECEPTOR AGONISTS | March 2010 | January 2013 | Allow | 34 | 2 | 0 | Yes | No |
| 12749185 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS AND CELL TELOMERE AND DISEASES OF CELL PROLIFERATION BY USING HETEROANNELATED ANTHRAQUINONE DERIVATIVE COMPOUNDS | March 2010 | January 2013 | Allow | 34 | 1 | 1 | Yes | No |
| 12673555 | QUINOLIN-4-ONE AND 4-OXODIHYRDOCINNOLINE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) | February 2010 | September 2012 | Allow | 31 | 1 | 0 | No | No |
| 12703604 | Benzazole Derivatives, Compositions, And Methods Of Use As Aurora Kinase Inhibitors | February 2010 | October 2012 | Allow | 32 | 1 | 1 | No | No |
| 12669865 | INHIBITOR OF THE DIFFERENTIATION OF T CELLS INTO TH1 CELLS | January 2010 | November 2012 | Allow | 34 | 1 | 1 | No | No |
| 12652456 | SMALL MOLECULE BCL-X1/BCL-2 BINDING INHIBITORS | January 2010 | June 2012 | Allow | 29 | 0 | 1 | No | No |
| 12664664 | POTENTIATION OF CANCER CHEMOTHERAPY BY 7-(2, 5- DIHYDRO- 4-IMIDAZO [1, 2-A] PYRIDINE-3-YL-2,5-DIOXO-IH-PYRROL-3-YL)-9-FLUORO-1,2,3,4 TETRAHYDRO -2-(1-PIPERIDINYL-CARBONYL)-PYRROLO [3,2,1-JK] [1,4] BENZODIAZEPINE | December 2009 | August 2012 | Allow | 32 | 1 | 1 | No | No |
| 12629134 | PHARMACEUTICAL COMPOSITIONS OF SHORT-ACTING SEDATIVE HYPNOTIC AGENT | December 2009 | April 2011 | Allow | 16 | 1 | 0 | No | No |
| 12524695 | N, N -DIMETHYL IMIDODICARBONIMIDIC DIAMIDE ACETATE, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | November 2009 | September 2011 | Allow | 26 | 1 | 0 | Yes | No |
| 12596488 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE (S1P) AGONISTS | October 2009 | July 2012 | Allow | 33 | 1 | 0 | No | No |
| 12577436 | METHOD OF ACTIVATING NK CELLS | October 2009 | December 2012 | Allow | 38 | 1 | 1 | Yes | No |
| 12594093 | OXAZOLIDINONE DERIVATIVE HAVING INHIBITORY ACTIVITY ON 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | September 2009 | April 2011 | Allow | 18 | 1 | 1 | No | No |
| 12528606 | TREATMENT OF CANCER WITH BIO AND CHEMOTHERAPY | August 2009 | September 2012 | Allow | 36 | 1 | 1 | No | No |
| 12526164 | INHIBITORS OF AKT ACTIVITY | August 2009 | December 2012 | Allow | 40 | 2 | 1 | No | No |
| 12524754 | COMPOSITION FOR TREATMENT OF UNDIFFERENTIATED GASTRIC CANCER | July 2009 | April 2012 | Allow | 33 | 1 | 1 | No | No |
| 12497879 | PROGESTERONE FOR THE TREATMENT OR PREVENTION OF SPONTANEOUS PRETERM BIRTH | July 2009 | September 2010 | Allow | 15 | 2 | 0 | Yes | No |
| 12519263 | CHEMOTHERAPEUTIC FLAVONOIDS, AND SYNTHESES THEREOF | June 2009 | September 2014 | Allow | 60 | 2 | 1 | Yes | No |
| 12479524 | DERMATOLOGICAL COMPOSITIONS AND METHODS | June 2009 | July 2011 | Allow | 26 | 2 | 0 | No | Yes |
| 12478587 | NOVEL COMPOUNDS | June 2009 | March 2012 | Allow | 34 | 1 | 1 | Yes | No |
| 12437008 | ADMINISTRATION OF 6-[3-(1-ADAMANTYL)-4-METHOXYPHENYL]-2-NAPHTHOIC ACID FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS | May 2009 | September 2010 | Allow | 16 | 0 | 0 | No | No |
| 12444592 | PYRIMIDYL DERIVATIVES AS PROTEIN KINASE INHIBITORS | April 2009 | September 2011 | Allow | 29 | 0 | 0 | No | No |
| 12384620 | NEUROPROTECTIVE SMALL ORGANIC MOLECULES, COMPOSITIONS AND USES OF RELATED THERETO | April 2009 | June 2010 | Allow | 15 | 1 | 1 | No | No |
| 12300350 | Synergistic Compositions Consisting Essentially of Combinations of Active Agents Selected from Oridonin, Wogonin and Isoliquiritigenin for the Prevention of Neoplasia | April 2009 | March 2015 | Allow | 60 | 3 | 0 | No | No |
| 12415391 | NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 | March 2009 | July 2012 | Allow | 40 | 1 | 1 | Yes | No |
| 12441242 | PYRAZOLOPYRIDINE, INDAZOLE, IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE, PYRAZOLOPYRAZINE AND PYRAZOLOPYRIDINE DERIVATIVES AS STIMULATORS OF GUANYLATE CYCLASE FOR CARDIOVASCULAR DISORDERS | March 2009 | July 2012 | Allow | 40 | 2 | 1 | Yes | No |
| 12401254 | KINASE INHIBITOR | March 2009 | May 2012 | Allow | 39 | 2 | 1 | No | No |
| 12337970 | CXCR2 ANTAGONISTS | December 2008 | September 2013 | Allow | 57 | 2 | 1 | No | No |
| 12338176 | PYRAZOLYLBENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND USE THEREOF | December 2008 | April 2015 | Allow | 60 | 5 | 1 | Yes | No |
| 12337980 | CXCR2 INHIBITORS | December 2008 | November 2014 | Allow | 60 | 4 | 1 | No | No |
| 12300508 | Uses for 4,17B-dihydroxyandrost-4-ene-3-one | November 2008 | April 2015 | Allow | 60 | 4 | 1 | Yes | No |
| 12300358 | INHIBITORS OF AKT (PROTEIN KINASE B) | November 2008 | April 2011 | Allow | 29 | 0 | 0 | No | No |
| 12283946 | USE OF R (+) -N-PROPARGYL-1-AMINOINDAN TO TREAT OR PREVENT HEARING LOSS | September 2008 | December 2011 | Allow | 39 | 3 | 0 | No | No |
| 12206776 | AGAVE SYRUP EXTRACT HAVING ANTICANCER ACTIVITY | September 2008 | December 2012 | Allow | 51 | 3 | 1 | Yes | Yes |
| 12172202 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER, TUMORS, AND TUMOR-RELATED DISORDERS | July 2008 | March 2012 | Allow | 44 | 1 | 1 | No | No |
| 11887368 | TRICYCLIC 1,2,4-TRIAZINE OXIDES AND COMPOSITIONS FOR THERAPEUTIC USE IN CANCER TREATMENTS | June 2008 | March 2011 | Allow | 41 | 0 | 0 | Yes | No |
| 12096884 | TREATMENT OF DRUG-RESISTANT TUMORS | June 2008 | October 2010 | Allow | 28 | 2 | 0 | No | No |
| 12081661 | Iminosugar treatment of tumors | April 2008 | September 2014 | Allow | 60 | 3 | 1 | Yes | Yes |
| 12103182 | ADMINISTRATION OF 6-[3-(1-ADAMANTYL)-4-METHOXYPHENYL]-2-NAPHTHOIC ACID FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS | April 2008 | September 2010 | Allow | 29 | 2 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner JEAN-LOUIS, SAMIRA JM.
With a 25.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 42.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner JEAN-LOUIS, SAMIRA JM works in Art Unit 1642 and has examined 126 patent applications in our dataset. With an allowance rate of 98.4%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 35 months.
Examiner JEAN-LOUIS, SAMIRA JM's allowance rate of 98.4% places them in the 90% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by JEAN-LOUIS, SAMIRA JM receive 1.78 office actions before reaching final disposition. This places the examiner in the 36% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by JEAN-LOUIS, SAMIRA JM is 35 months. This places the examiner in the 38% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +0.2% benefit to allowance rate for applications examined by JEAN-LOUIS, SAMIRA JM. This interview benefit is in the 19% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 39.7% of applications are subsequently allowed. This success rate is in the 90% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 60.9% of cases where such amendments are filed. This entry rate is in the 87% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 66.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 53% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 78.9% of appeals filed. This is in the 71% percentile among all examiners. Of these withdrawals, 80.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 44.4% are granted (fully or in part). This grant rate is in the 35% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 16.7% of allowed cases (in the 97% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.2% of allowed cases (in the 77% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.